Skip to main content

Advertisement

SpringerLink
Log in

Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population

  • Research Article
  • Published:
Tumor Biology

Abstract

Chemokines are small inducible pro-inflammatory cytokines. In the present study, we tested association of chemokine single nucleotide polymorphisms (SNPs) viz., CCR5∆32, CXCL12G801A and CXCR2C1208T genes in bladder cancer (BC) patients and normal healthy controls of north Indians. Genotyping of the above SNPs were done in 200 BC cases and 200 healthy controls, using RFLP and amplification refractory mutation system–polymerase chain reaction methodology. A significant association was found in CXCL12G801A with BC risk. In case of CXCL12G801A polymorphism, the heterozygous (GA) genotype showed significantly high risk (p < 0.001, odds ratio (OR) = 2.72), whereas A allele carrier (GA + AA) also showed risk with BC (p < 0.001, OR = 2.44). In CXCR2C1208T polymorphism, the variant genotype (TT) showed significant risk for BC (p = 0.028, OR = 1.58). The variant allele (T) of CXCR2C1208T polymorphism was found to be associated with BC risk (p = 0.003, OR = 1.29). Interestingly, smoking was also found to modulate 1.16-fold risks for BC in case of CXCR2C1208T, variant genotype (TT). Upon analyzing the gene–gene interaction between CXCR2C1208T and CXCL12G801A, the combination CT-GA showed 4-fold risk for BC (p = 0.009). Our results indicated that polymorphism in CXCR2C1208T and CXCL12G801A showed high risk for BC in north Indian population. However, CCR5∆32 exhibited no association. Study with large sample size and diverse ethnicity are required to validate these observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Raman D, Baugher PJ, Thu YM, et al. Role of chemokines in tumor growth. Cancer Lett. 2007;256:137–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Morgan D, Mahe C, Mayanja B, et al. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002;324:193–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Horuk R. Molecular properties of the chemokines receptor family. Trends Pharmacol Sci. 1994;15:159–65.

    Article  CAS  PubMed  Google Scholar 

  4. Ruster M, Sperschneider H, Funfstuck R, Stein G, Grone HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol. 2004;61:30–9.

    Article  CAS  PubMed  Google Scholar 

  5. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.

    Article  CAS  PubMed  Google Scholar 

  6. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–3.

    Article  CAS  PubMed  Google Scholar 

  7. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:S460–75.

    Article  CAS  PubMed  Google Scholar 

  8. Apostolakis S, Baritaki S, Kochiadakis GE, et al. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res. 2007;119:63–71.

    Article  CAS  PubMed  Google Scholar 

  9. Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13:5056–62.

    Article  CAS  PubMed  Google Scholar 

  10. de Oliveira CE, Cavassin GG, Perim Ade L, et al. Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J Clin Lab Anal. 2007;21:49–54.

    Article  PubMed  Google Scholar 

  11. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.

    Article  CAS  PubMed  Google Scholar 

  12. Brant E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204–16.

    Article  Google Scholar 

  13. Renzoni E, Lympany P, Sestini P. Distribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000;43:1633–40.

    Article  CAS  PubMed  Google Scholar 

  14. Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol. 2008;7:618–26.

    Article  Google Scholar 

  15. Miller SA, Dykes DD, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Singh R, Kapoor R, Srivastava A, et al. Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in north Indian renal transplant recipients. Scand J Immunol. 2009;69:51–6.

    Article  CAS  PubMed  Google Scholar 

  17. Manchanda PK, Singh R, Mittal RD. Cytokine (IL-10–1082 and -819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in north Indian patients with end-stage renal disease. DNA Cell Biol. 2009;28:177–83.

    Article  CAS  PubMed  Google Scholar 

  18. Ahluwalia TS, Khullar M, Ahuja M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy intype 2 diabetes among Asian Indians. PLoS One. 2009;4:51–68.

    Article  Google Scholar 

  19. D’Angelo R, Crisafulli C, Rinaldi C, et al. CCR5Δ32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int. 2011;2011:153–82.

    Google Scholar 

  20. Srivastava A, Pandey SN, Choudhuri G, et al. CCR5 Delta32 polymorphism associated with gallbladder cancer susceptibility. Scand J Immunol. 2008;67:516–22.

    Article  CAS  PubMed  Google Scholar 

  21. Kucukgergin C, Isman FK, Dasdemir S, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 2012;10(511):7–11.

    Article  Google Scholar 

  22. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2–64I and CXCL12–3a in the development of sporadic breast cancer. J Med Genet. 2004;41:e59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Paterlini MG. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J. 2002;83:3012–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kruszyna L, Lianeri M, Rubis B, et al. CCL2–2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep. 2010;38:1263–7.

    Article  PubMed  Google Scholar 

  25. Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282–8.

    Article  PubMed  Google Scholar 

  26. Dimberg J, Hugander A, Löfgren S, et al. Polymorphism and circulatinglevels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2007;1:11–5.

    Google Scholar 

  27. Ku FC, Tsai CR, Der Wang J, et al. Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:25–30.

    Article  CAS  PubMed  Google Scholar 

  28. Vairaktaris E, Vylliotis A, Spyridonodou S, et al. DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Anticancer Res. 2008;28:271–5.

    CAS  PubMed  Google Scholar 

  29. Lian LH, Kee BP, Ng HL, et al. Lack of association between RANTES-28, SDF-1 gene polymorphisms and systemic lupus erythematosus in the Malaysian population. Genet Mol Res. 2011;10:2841–50.

    Article  CAS  PubMed  Google Scholar 

  30. Işman FK, Kucukgergin C, Daşdemir S, et al. Association between SDF1-3′A or CXCR4 gene polymorphisms with predisposition toand clinicopathological characteristics of prostate cancer with or without metastases. Mol Biol Rep. 2012;39:1073–9.

    Article  Google Scholar 

  31. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–53.

    Article  CAS  PubMed  Google Scholar 

  33. Javor J, Bucova M, Cervenova O, et al. Genetic variations of interleukin-8, CXCR1 and CXCR2 genes and risk of acutepyelonephritis in children. Int J Immunogenet. 2012;39:338–45.

    Article  CAS  PubMed  Google Scholar 

  34. Duymaz-Tozkir J, Yilmaz V, Uyar FA, et al. Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet’s disease. J Rheumatol. 2005;32:93–7.

    CAS  PubMed  Google Scholar 

  35. Snoussi K, Mahfoudh W, Bouaouina N, et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;12:10–283.

    Google Scholar 

  36. Salim PH, Jobim M, Bredemeier M, et al. Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis. Cytokine. 2012;60:473–7.

    Article  CAS  PubMed  Google Scholar 

  37. Ben-Baruch A. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5:31–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are thankful to the urologists in our department for providing bladder cancer samples and relevant clinical information of patients. Vibha Singh is thankful to ICMR New Delhi for providing Senior Research Fellowship (SRF) and Praveen Kumar Jaiswal is thankful to UGC New Delhi for providing Junior Research Fellowship (JRF).

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Science, Raebareli Road, Lucknow, 226014, Uttar Pradesh, India

    Vibha Singh, Praveen Kumar Jaiswal, Rohit Kapoor, Rakesh Kapoor & Rama Devi Mittal

Authors
  1. Vibha Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Praveen Kumar Jaiswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rohit Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rakesh Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rama Devi Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rama Devi Mittal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, V., Jaiswal, P.K., Kapoor, R. et al. Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. Tumor Biol. 35, 4765–4772 (2014). https://doi.org/10.1007/s13277-014-1624-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1624-7

Keywords

Search

Navigation